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included. Pain was assessed with the Premature Infant Pain 
Profile (PIPP) and the COMFORTneo score. Peak plasma 
 concentrations of paracetamol were determined.  Results: A 
total of 60 patients were included in the paracetamol 
dose groups (median gestational age = 27.8, IQR: 25.7–29.2 
weeks). PIPP scores were comparable: median = 8 (IQR: 
6–10.5), 7 (IQR: 6–9), and 8 (IQR: 6–10) for the 10-, 15-, and 
20-mg/kg paracetamol groups, respectively ( p = 0.94).
COMFORTneo scores were not statistically different be-
tween the different paracetamol dose groups ( p = 0.35). 
All randomized subjects, except for 3 who received 10 mg/
kg of paracetamol, had peak paracetamol concentrations 
>9 mg/L. PIPP ( p = 0.78) and COMFORTneo ( p = 0.08) scores 
were also comparable between paracetamol- and sucrose-
treated patients.  Conclusions: We found no analgesic ben-
efit from intravenous paracetamol studied in different single 
doses over sucrose for PICC placement in preterm infants. 
Paracetamol is not a suitable analgesic for this procedure in 
preterm infants.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: The availability of a safe and effective pharma-
cological therapy to reduce procedural pain in preterm in-
fants is limited. The effective analgesic single dose of intra-
venous paracetamol in preterm infants is unknown. Com-
parative studies on efficacy of different paracetamol doses 
in preterm infants are lacking.  Objectives: To determine the 
analgesic effects of different single intravenous paracetamol 
doses on pain from peripherally inserted central catheter 
(PICC) placement in preterm infants.  Methods: In a blinded 
randomized controlled trial, the analgesic effects of 10-, 15-, 
and 20-mg/kg single-dose intravenous paracetamol before 
PICC placement were compared in neonates with a gesta-
tional age <32 weeks. Secondly, a separate age-matched 
nonrandomized control group receiving oral sucrose was
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 Introduction 
 Today, pain assessment is an essential component of 
medical care for preterm infants who undergo many 
painful procedures  [1, 2] . Analgesia is necessary to pro-
tect against the negative short- and long-term conse-
quences of pain from skin-breaking procedures such as 
changes in brain development  [3] . The analgesic proper-
ties of sucrose to reduce procedural pain have been ques-
tioned although its administration is the standard of care 
in many NICUs  [4] . Long-acting opioids, such as mor-
phine, do not effectively reduce pain from heel sticks in 
preterm infants  [5] . The reluctance to use strong analge-
sic drugs in newborns is triggered by studies in rodents 
showing accelerated neuronal apoptosis  [6] . Such find-
ings warrant studies on the effectiveness and safety of 
other analgesics, such as paracetamol. 
 Paracetamol is the most used drug to relieve mild to 
moderate pain in children and adults. Its safety and effi-
cacy after intravenous administration have not yet been 
proven in preterm infants.
 The objective of this study was to determine the anal-
gesic effect of 3 different single doses of paracetamol be-
fore peripherally inserted central catheter (PICC) place-
ment in preterm infants in a randomized controlled trial. 
Additionally, a nonrandomized age-matched sucrose 
control group was added.
 Methods 
 Design, Patients, and Setting 
 This multicenter, blinded, randomized controlled trial was per-
formed from October 2010 until October 2013 at the level III 
NICUs of the Erasmus MC-Sophia Children’s Hospital in Rotter-
dam and the Isala Clinics in Zwolle, the Netherlands. Recruitment 
of eligible patients was strictly performed by members of the re-
search team. Subjects were randomly allocated to 10-, 15-, or 20-
mg/kg single-dose paracetamol (Perfalgan © ; Bristol-Meyers 
Squibb) given before PICC placement. 
 Inclusion criteria were gestational age <32 weeks, an indwell-
ing arterial catheter, and PICC placement in the first 7 days of life. 
Patients who had already received analgesics or sedatives were 
excluded. NSAID use for patent ductus arteriosus was allowed. 
The study was conducted according to European Good Clinical 
Practice regulations and registered in the Dutch Trial Registry 
(trial No. 2290); Ethics Review Board approval (MEC-2009-250) 
and written informed consent from parents/legal guardians was 
obtained. 
 The Ethics Review Board initially did not allow the sucrose 
control group in the randomized controlled trial. Instead, after fin-
ishing including patients for this trial, and with approval of the 
Erasmus MC Ethics Review Board (MEC-2014-386), we applied 
the same pain assessment instruments to a group of age-matched 
patients who were given oral sucrose before PICC placement. 
Analysis of the data of all patients (paracetamol and sucrose group) 
took place after finishing recruitment of patients for the sucrose 
group.
 Outcome 
 Pain assessed with the validated Premature Infant Pain Profile 
(PIPP) score  [7, 8] was the primary outcome. Baseline data were 
assessed at  t = 0 (15 min prior to procedure) and pain was assessed 
from the start of the skin-breaking procedure of the PICC place-
ment until 30 s. We used sterile transparent covers for proper judg-
ment of the neonate. A PIPP score <7 reflects no/minimal pain and 
 ≥ 7–12 mild/moderate pain; scores >12 reflect severe pain  [7] . Be-
cause the PIPP was recently revised (drops in heart rate added), we 
analyzed how inclusion of heart rate change would have affected 
PIPP assessment  [9] . PIPP scores were assigned by trained mem-
bers of the research team (interrater reliability linearly weighted 
Cohen’s κ >0.65).
 The COMFORTneo score  [10] was the secondary outcome and 
applied by trained nurses (interrater reliability linearly weighted Co-
hen’s κ >0.65). A COMFORTneo score between 14 and 30 indicates 
“pain or distress” (sensitivity of 0.81 and specificity of 0.90)  [10] . 
 Interventions 
 The procedure was started directly after paracetamol infusion 
(in 15 min through a peripheral venous cannula) and performed 
by experienced neonatologists or nurse practitioners. No addition-
al sucrose was given.
 In the separate sucrose study group, 0.5 mL (if <1,000 g) or 1.0 
mL ( ≥ 1,000 g) of sucrose 24% (EPMC Pharma, Belgium) was ad-
ministered in the buccal cavity together with the use of a pacifier 
2 min before PICC placement.
 A blood sample of 200 μL was taken to determine peak plasma 
levels 15–20 min after infusion. 
 While the PICC was inserted, one of the researchers assigned 
the PIPP score after observation for 30 s. In addition, the attending 
nurse assigned the COMFORTneo score during the intervention 
after observation for 2 min. Subjects in the control group receiving 
sucrose were assessed in exactly the same way.
 Sample Size Calculation 
 With 20 infants per treatment group, the power to detect dif-
ferences in the mean PIPP scores of 1 point equals 83%. This cal-
culation is based on the reported SD of PIPP scores assigned for a 
skin-breaking procedure, i.e., 1.4 points  [8] . Thus, the total sample 
size was 60 subjects for the 3 paracetamol conditions. 
 Randomization 
 Stratified randomization for the 3 paracetamol dose groups was 
performed for 2 gestational age groups (24–28 weeks and 28 1/7 –32 
weeks) by using sequentially numbered, sealed, and opaque enve-
lopes. The envelopes for the different age groups were kept apart 
(marked A and B, respectively, and both numbered from 1 to 30). 
A nurse (practitioner) not involved in the care of the included pa-
tient opened the envelope for the applicable age group that con-
tained the allocated dose of paracetamol. For each new patient, the 
next subsequently numbered envelope was opened. Patients could 
be included only once.
 Both the researchers and all nursing and medical staff taking 
care of the subjects were blinded to the administered dose of 
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paracetamol. The medication was prepared by a nurse (practitio-
ner) from another NICU unit. Unbinding of the study medication 
took place after all subjects were included.
 Statistical Analysis 
 Background characteristics between the paracetamol groups 
and the sucrose group were compared using Fisher exact tests for 
categorical variables and Mann-Whitney U tests for continuous 
variables. 
 Nonnormally distributed continuous variables were compared 
between the paracetamol groups using Kruskal-Wallis tests. Linear 
regression analysis with PIPP scores as the outcome variable was 
applied to determine the effects of the treatment (using 3 dummy 
variables for the 4 treatment conditions) as the predictor variable. 
In addition, administration of NSAIDs within 24 h before the pro-
cedure was added as a covariate. The distribution of the COM-
FORTneo and PIPP scores between the total paracetamol group 
and sucrose group were tested with Mann-Whitney U tests. Statis-
tical significance was set at  p < 0.05 (2-sided). Data were analyzed 
using the intention-to-treat principle. 
 Results 
 In total, we assessed 266 patients for eligibility and ran-
domized 60 patients to receive paracetamol ( Fig. 1 ): 30 
patients per gestational age group. All patients received 
the predetermined dose and all patients were included 
into the analyses. Background characteristics are shown 
in  Table 1 .
 PIPP scores for the 3 different paracetamol groups 
were comparable: median = 8 (IQR: 6–10.5), 7 (IQR: 
6–9), and 8 (IQR: 6–10) for the 10-, 15-, and 20-mg/kg 
paracetamol groups, respectively ( p = 0.94). These scores 
reflect mild to moderate pain ( Table 2 ;  Fig. 2 ).
 The COMFORTneo scores had a median of 12 (IQR: 
10–14.8), 14 (IQR: 11–19.8), and 14 (IQR: 11–20) in the 
10-, 15-, and 20-mg/kg paracetamol groups, respectively 
( p = 0.35) ( Table 2 ). Paracetamol plasma peak concentra-
tions increased with paracetamol dose with median levels 
of 10.6 mg/L (IQR: 9.5–11.6), 16.5 mg/L (IQR: 14.9–19.6), 
Assessed for eligibility (n = 226)
Allocated to 10 mg/kg
paracetamol (n = 20)
Lost to follow-up (n = 0) Lost to follow-up (n = 0) Lost to follow-up (n = 0) Lost to follow-up (n = 0)
Analyzed (n = 20) Analyzed (n = 20)
Randomized (n = 60)
An
al
ys
is
Fo
llo
w
-u
p
Al
lo
ca
tio
n
En
ro
llm
en
t
Analyzed (n = 20) Analyzed (n = 20)
Allocated to 15 mg/kg
paracetamol (n = 20)
Allocated to 20 mg/kg
paracetamol (n = 20)
Control group: allocated 
to sucrose (n = 20)
Excluded (n = 206)
– Parental refusal (n = 51)
– Other reasons  (n = 155): death; 
language barrier, missing due to 
logistic reasons, early transfer 
to other hospital
 Fig. 1. Participant flowchart. 
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and 21.3 mg/L (IQR: 18.5–22.1), for the 10-, 15-, and 20-
mg/kg paracetamol groups, respectively ( p < 0.001). All 
subjects, except for 3 who received 10 mg/kg of para-
cetamol, had a peak plasma concentration >9 mg/L.
 Additionally, 20 separate nonrandomized age-
matched control patients were included and received su-
crose prior to PICC placement. Background characteris-
tics were comparable ( Table 1 ). Clinical outcome data are 
shown in  Table 3 . PIPP scores were not different com-
pared to the paracetamol groups (median = 8, IQR: 6.3–
10;  p = 0.78). Regression analysis showed that PIPP scores 
were comparable between the 4 treatment groups. 
NSAIDs added as a covariate did not significantly affect 
the PIPP scores ( p = 0.60) either. 
 The median COMFORTneo scores of the sucrose-
treated patients were available for 16 patients and had a 
median of 12 (IQR: 10–14.8), and were not statistically 
different compared to the total paracetamol-treated pa-
tients ( p = 0.08).
 Table 1.  Background characteristics of the treatment groups
Characteristics  Paracetamol Additional
control group
sucrose (n = 20)10 mg/k g(n = 20)
15 mg/kg
(n = 20)
20 mg/kg
(n = 20)
Median gestational age (range), weeks 27.8 (24.0 – 31.1) 27.9 (24.2 – 30.4) 28.8 (24.2 – 30.3) 27.9 (24.1 – 31.4)
Median birth weight (range), g 970 (462 – 1,550) 988 (475 – 1,440) 885 (630 – 1,380) 898 (520 – 1,330)
SGA, n (%) 4 (20) 5 (25) 7 (35) 8 (40)
Sex, n (%)
Boy
Girl
10 (50)
10 (50)
10 (50)
10 (50)
8 (40)
12 (60)
10 (50)
10 (50)
Antenatal steroids, n (%) 19 (95) 18 (90) 18 (90) 18 (90)
PIH, n (%) 4 (20) 7 (35) 3 (15) 5 (25)
PPROM, n (%)
Median Apgar 1′ (IQR)
Median Apgar 5′ (IQR)
Median line placement PNA (IQR)
3 (15)
6 (4.3 – 7.8)
7.5 (6.3 – 9.0)
4.5 (2 – 6)
3 (15)
6 (5.0 – 8.0)
8 (7.0 – 9.0)
6 (5 – 6)
2 (10)
6 (5.0 – 8.0)
8 (6.5 – 9.0)
6 (1.3 – 7)
1 (5)
7.5 (4.3 – 9.0)
9 (8.0 – 9.0)
3 (1 – 7)
 All background characteristics were comparable between the paracetamol groups and the sucrose group. SGA, small for gestational 
age; PIH, pregnancy-induced hypertension; PPROM, prolonged premature rupture of membranes; PNA, postnatal age.
 Table 2.  PIPP and COMFORTneo scores during PICC placement
Pain assessment during
procedure
Paracetamol p value4 Sucrose 24%
(n = 20)
p value4
10 mg/kg
(n = 20)
15 mg/kg
(n = 20)
20 mg/kg
(n = 20)
Median PIPP score (IQR) 8 (6 – 10.5) 7 (6 – 9) 8 (6 – 10) 0.94 8 (6.3 – 10) 0.78
PIPP score1, n (%)
<7 9 (45) 11 (55) 8 (40) 9 (45) 0.46
7 – 12 10 (50) 8 (40) 10 (50) 11(55)
>12 1 (5) 1 (5) 2 (10) –
Median COMFORTneo score2 (IQR) 12 (10 – 14.8) 14 (11 – 19.8) 14 (11 – 20) 0.35 11 (10 – 13.8) 0.08
COMFORTneo score 14–303, n (%) 6 (30) 10 (50) 10 (50) 4 (25) 0.18
 PICC, peripherally inserted central catheter; PIPP, Premature Infant Pain Profile; 1 PIPP <7 no to mild pain; 7 – 12 moderate pain; 
≥13 severe pain. 2 Three COMFORTneo scores were missing. 3 A COMFORTneo score between 14 and 30 suggests pain and/or distress. 
4 Fisher exact and Kruskal-Wallis tests were applied as appropriate. 
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 Besides the PIPP, we also studied heart rate as includ-
ed in the revised PIPP which takes both a rise and drop in 
heart rate into account as unwanted. Overall (3 para-
cetamol dose groups and a sucrose group), 20% of our 
patients showed a drop in heart rate ( Fig. 3 ).
 Discussion 
 Pain scores assigned to preterm infants during PICC 
placement after different paracetamol doses were compa-
rable. Most patients showed mild to moderate pain. Com-
parison with a sucrose group suggested that paracetamol 
was not more effective but also noninferior to sucrose, 
PI
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in
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pr
oc
ed
ur
e
Sucrose
Treatment
>12: severe pain
7: mild to 
moderate pain
Gestational age
24–28 weeks
28.1–32 weeks
10 mg/kg 20 mg/kg15 mg/kg
Paracetamol
17
22
12
7
2
*
 Fig. 2. PIPP scores during PICC placement 
( n = 10 in each box). 
 Table 3.  Clinical outcome data
Characteristics  Paracetamol Additional control group
sucrose 24%
(n = 20)10 mg/kg (n = 20)
15 mg/kg
(n = 20)
20 mg/kg
(n = 20)
RDS 15 (75) 16 (80) 13 (65) 14 (70)
Mechanical ventilation 15 (75) 16 (80) 14 (70) 13 (65)
Surfactant 14 (70) 15 (75) 14 (70) 13 (65)
PDA 8 (40) 7 (35) 12 (60) 8 (40)
Treatment indomethacin 3 (15) 2 (10) 5 (25) 0
Treatment ibuprofen 2 (10) 3 (15) 4 (20) 8 (40)
Surgery 5 (25) 2 (10) 4 (20) 1 (5)
Sepsis 9 (45) 9 (45) 10 (50) 12 (60)
NEC 1 (5) 1 (5) 2 (10) 1 (5)
FIP 0 2 (10) 2 (10) 0
Surgery NEC 0 1 (5) 3 (15) 1 (5)
IVH 2 (10) 5 (25) 6 (30) 4 (20)
Death 0 4 (20) 2 (10) 2 (10)
 Values are presented as n (%). RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; NEC, necrotizing enterocolitis; 
FIP, focal intestinal perforation; IVH, intraventricular hemorrhage.
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which makes paracetamol a drug of choice in those in-
fants with a contraindication for sucrose. PICC place-
ment has been rated painful (8 on a scale of 0–10) by cli-
nicians  [11] .
 Comparative studies on efficacy of different para ceta-
mol doses in preterm infants are lacking. While there are 
data from pharmacokinetics studies  [12, 13] , the pharma-
codynamics of paracetamol in neonates are poorly de-
scribed. Allegaert et al. [14] showed a reduction of pain 
after 20 mg/kg of paracetamol in preterm and term in-
fants suffering from delivery trauma. Pharmacokinetics 
studies on intravenous paracetamol in preterm infants 
also suggest that a loading dose of 20 mg/kg intravenous 
paracetamol for neonates with postconceptional ages of 
28–32 weeks and body weights above 1.5 kg is sufficient 
for pain relief  [15] . Pharmacokinetics/pharmacodynam-
ics data in older infants suggest a target plasma concen-
tration of >9 mg/L  [13] . Our study showed plasma con-
centrations >9 mg/L in 95% of all subjects. As a conse-
quence, the absence of pain relief by paracetamol in our 
study can probably not be explained by paracetamol dos-
es that were too low. Our peak plasma concentrations 
even suggest that a 10- or 15-mg/kg loading dose might 
be sufficient. 
 The most obvious explanation of our findings is that 
paracetamol does not relieve pain associated with acute 
skin-breaking procedures  [16] . The add-on value of 
paracetamol for acute procedural analgesia can be ques-
tioned, as confirmed in previous studies on venous sam-
pling and heel lancing  [17] . A Cochrane review in 2015 
showed no significant reduction in pain by paracetamol 
associated with heel lance or eye examinations  [16] , al-
though Kabatas et al. [18] recently published results of 
reduced PIPP scores during ROP screening compared to 
placebo (12 [9–13] vs. 14 [13–15];  p = 0.01) after a single 
dose of paracetamol  [19] .
 Thus, other analgesics need to be considered to im-
prove analgesic therapy for PICC placement. A study 
with EMLA showed no pain relief compared to oral glu-
cose 20% in preterm infants (gestational age: 28–37 
weeks)  [18] , and tetracaine 4% gel was not beneficial in 
decreasing procedural pain associated with PICC place-
ment in very small infants  [20, 21] .  Table 4 shows an over-
view of PIPP scores for different analgesic treatments 
during skin-breaking procedures. A large variability be-
tween studies and within study groups can be seen. This 
suggests that there might be many more variables that 
contribute to pain expression. 
 Systemic administration of the short-acting opioid 
remifentanil might have more suitable analgesic qualities 
for acute procedural interventions in newborns  [22] . 
PIPP scores during PICC placement were significantly 
lower (p < 0.05) after remifentanil compared to sucrose 
(6.1 ± 1.4 vs. 8.6 ± 1.7)  [23] . Shin et al.  [25]  showed a remi-
fentanil dose-effect relationship with lower PIPP scores 
during PICC placement with high-dose (0.25 μg/kg) ver-
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 Fig. 3. Peri-intervention changes in heart rate (left panel) and oxygen saturation (right panel). HR, heart rate. 
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sus low-dose (0.1 μg/kg) remifentanil in 14 preterm in-
fants. On the other hand, remifentanil use is related to 
adverse effects such as respiratory insufficiency and chest 
wall rigidity, making broader use or use outside an inten-
sive care setting less feasible. Furthermore, skin-breaking 
procedures are performed multiple times per day, making 
remifentanil for all procedures less obvious.
 Pain assessment in very preterm infants remains a 
challenge. Numerous pain assessment instruments are 
available, but only a few take gestational age into account, 
like the PIPP. The PIPP includes changes in heart rate and 
oxygen saturation, which might better reflect acute pain. 
Other than the originally published PIPP, the revised 
PIPP  [9] takes both a rise and a drop in heart rate into ac-
count. The fact that 20% of our patients showed a drop in 
heart rate proves the usefulness of the revised PIPP score 
in future studies. 
 Several limitations of this study should be addressed. 
First, the study was not powered to determine a difference 
in either the COMFORTneo score or in proportions of 
infants with a PIPP score >7; to do so would require a 
much larger sample. Furthermore, the sucrose control 
group was added afterwards and used to compare pain 
scores with the randomized patients. The sucrose group 
was age-matched, but a selection bias cannot be ruled out. 
Second, the assessors of the sucrose group were not blind-
ed to the administered therapy (sucrose), although they 
were not aware of the assessed pain scores in the 
paracetamol-treated infants; theoretically, this could have 
attributed to a bias in assessed results. Third, we demon-
strated in this study that paracetamol was not more effec-
tive than sucrose for PICC placement, but we did not look 
at the additional effect of paracetamol in combination 
with sucrose. Fourth, 7 patients received NSAIDs for 
PDA treatment, reflecting standard clinical care of very 
preterm neonates. These patients were not excluded, but 
the use of NSAIDs was added as a covariate in our analy-
ses. No influence on pain scores was found. Fifth, to avoid 
infusion site discomfort, the paracetamol was adminis-
tered over 15 min. The PICC placement was started di-
rectly after paracetamol infusion. It is not totally clear if 
paracetamol in these preterm infants has a direct effect at 
peak plasma levels, or if there is a certain, unknown delay. 
In our study, the time period may not have been long 
enough to reach optimal analgesia. Still, the peak plasma 
levels seemed to be adequate when compared to studies 
in older infants. Finally, we were not able to study safety 
in our study. The trial was underpowered to conclude 
anything about safety of paracetamol in very preterm 
newborns. Liver and kidney function were not routinely 
screened before and after administration of paracetamol 
of all patients. 
 Table 4.  Overview of different analgesic treatment on PIPP scores for venipunctures
GA, 
weeks
Total,
n
Placebo/
no treatment
Mean PIPP
± SD
Pharmacological
treatment
Mean PIPP
± SD
Sugar solution/
breastfeeding
Mean PIPP
± SD
Venipuncture
Carbajal [26] ≥37 180 placebo 11.3 ± 3.17 breastfeeding
glucose 30%
5.18 ± 3.86
4.38 ± 3.82
Gradin [27] ≥39 120 breastfeeding
glucose 30%
10.37 ± 2.46
8.26 ± 3.9
Ahn [28] 25 – 41 110 no 6.66 ± 3.23
Taddio [29] >36 240 sterile water 8.9 ± 3.97 sucrose 24% 5.7 ± 4.0
Biran [30] 25 –36 76 sucrose 30% + EMLA 7.2 ± 3.2 sucrose 30% 8.5 ± 3.1
Sahoo [31] 37 160 sterile water 11.1 ± 3.94 dextrose 25%
expressed breast milk
5.22 ± 3.33
6.84 ± 4.19
PICC placement
Lemyre [32] 24 – 41 54 skin moisturizer 7.71 ± 4.76 tetracaine 4% 7.62 ± 4.76
Lago [25] <32 44 placebo 9 remifentanil 7
Shin [24] <32 14 remifentanil 0.1 μg/kg
remifentanil 0.25 μg/kg
7.40 ± 2.80
4.86 ± 0.83
Roofthooft (current 
study)
24 – 32 80 PCM 10 mg/kg
PCM 15 mg/kg
PCM 20 mg/kg
8.05 ± 2.8
7.87 ± 2.13
8.30 ± 2.83
Sucrose 24% 8.15 ± 2.16
 PIPP, Premature Infant Pain Profile; GA, gestational age; PCM, paracetamol.
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